当前位置: X-MOL首页全球导师 国内导师 › 张章

个人简介

张章,男,博士,副研究员,硕士生导师。2003年毕业于安徽中医学院获医学学士学位,2006年于暨南大学获药理学硕士学位,2016年于暨南大学获医学博士学位。先后在中国科学院广州生物医药与健康研究院等机构从事肿瘤药物开发及机制研究。2017年2月加入暨南大学药学院工作。 主持国家、广东省、广州市等课题5项、横向课题3项;申请中国发明专利18项(其中已授权8项)、PCT专利6项;在Cancer Letters,Journal of Medicinal Chemistry等SCI期刊发表SCI论文45篇,其中第一/ 共一作者论文19篇;部分成果已实现产业转化,处于中国/美国不同临床研究阶段。 曾获广东省科技进步二等奖(2016年),广州市科技进步一等奖(2015年),第十三届中国药学会科学技术奖三等奖(2018年),中国科学院第四届青年创业大赛金奖(2011年),第三届“坪山麒麟杯”创新创业大赛团队组一等奖(2018年),中国科学院广州生物医药与健康研究院先进科技工作者(2011年)等荣誉。 基金项目 1) 国家重点研发计划政府间国际科技创新合作项目(SQ2019YFE010401),92万元,负责人 2) 国家自然基金面上项目(81973158),55万,负责人 3) 广东省重点研发领域(2019B020204002),210万,子课题负责人 4) 广东省自然科学基金面上项目(2019A1515011235),10万,负责人 5) 广州市基础与应用基础研究项目(202002030414),20万,负责人

研究领域

小分子靶向抗肿瘤药物的研究开发 抗肿瘤药物的作用及机制研究 肿瘤耐药机制及克服耐药的新方法研究

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Minhao Huang,# Yongjun Huang,# Jing Guo,# Lei Yu, Yu Chang, Xiaolu Wang, Jinfeng Luo, Yanhui Huang, Zhengchao Tu, Xiaoyun Lu, Yong Xu, Zhimin Zhang,* Zhang Zhang,* Ke Ding,*Pyrido[2, 3-d]pyrimidin-7(8H)-ones as New Selective Orally Bioavailable Threonine Tyrosine Kinase (TTK) Inhibitors , EUR J MED CHEM, https://doi.org/10.1016/j.ejmech.2020.113023 (IF=4.816) Liang Jiang†, Yuting Wang†, Qian Li†, Zhengchao Tu, Sihua Zhu, Sanfang Tu*, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*,Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation, Acta Pharmaceutica Sinica B, 2020,DOI: 10.1016/j.apsb.2020.11.009 (IF=7.01) Yunxin Duan# , Jie Wang# , Sihua Zhu, Zheng-Chao Tu , Zhang Zhang*, Shingpan Chan*, Ke Ding*, Design, Synthesis, and Structure-Activity Relationships (SAR) of 3-Vinylindazole Derivatives as New Selective Tropomyosin Receptor Kinases (Trk) Inhibitors, EUR J MED CHEM, DOI: 10.1016/j.ejmech.2020.112552 (IF=4.816) Shenyang Cui#, Yongjin Wang#, Yuting Wang#, Xia Tang, Jinfeng Luo, Xiaomei Ren, Lei Zhang, Zheng-Chao Tu, Yong Xu, Zhang Zhang*, Zhimin Zhang*, Xiaoyun Lu*, Ke Ding*, Design, Synthesis and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-2- methylbenzamides as New Tropomyosin receptor kinase (Trk) Inhibitors, EUR J MED CHEM, 2019, 179:470-482. (IF=4.816) Li Tan#, Zhang Zhang#, Donglin Gao#, Shingpan Chan, Jinfeng Luo, Zheng-Chao Tu, Zhi-Min Zhang, Ke Ding, Xiaomei Ren*, Xiaoyun Lu*.Quinolone Antibiotic Derivatives as New Selective Axl Kinase Inhibitors. EUR J MED CHEM, 2019, 166:318-327. (IF=4.816) Jian Zou#, Zhang Zhang#,*, Fang Xu#, Shengyang Cui, Chunli Qi, Jingfeng Luo, Zhen Wang, Xiaoyun Lu, Zhengchao Tu, Xiaomei Ren, Liyan Song*, Ke Ding*.GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. J Drug Target., 2019, 27(4):442-450. (IF=3.408) Qiuju Xun #, Zhang Zhang #, Jinfeng Luo, Linjiang Tong, Jian Zou, Yong Xu, Hua Xie, Xiaoyun Lu*, Ke Ding*. Structure-Based Design of 2-Oxo-3, 4-dihydropyrimido [4, 5-d] Pyrimidines as Novel Colony Stimulating Factor-1 Receptor (CSF1R) Kinase Inhibitors. Journal of Medicinal Chemistry. 2018, doi: 10.1021/acs.jmedchem.7b01612. (IF=6.259) Zhang Zhang, Ren Xiaomei, Lu Xiaoyun, Wang Deping, Hu Xianjing, Zheng Yi, Song Liyan ,Pang Hongwen,Yu Rongmin*,Ding Ke*, GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer letters, 2016, 375:172-178 (IF=6.375); Li Tan#, Zhang Zhang#, Donglin Gao, Jinfeng Luo, Zhenchao Tu, Zhengqiu Li, Lijie Peng,Xiaomei Ren,*and Ke Ding*, 4-Oxo-1, 4-Dihydroquinoline-3-Carboxamide Derivatives as Selective Axl Kinase Inhibitors, Journal of Medicinal Chemistry.2016, 59(14):6807-25(IF=5.889); Xiaomei Ren#, Xiaofen Pan#, Zhang Zhang#, Deping Wang, Xiaoyun Lu, Yang Bai, Donghai Wen, Huoyou Long, Jinfeng Luo, Yubing Feng, Xiaoxi Zhuang, Fengxiang Zhang, Jianqi Liu, Fang Leng, Xingfen Lang, Zhengchao Tu, Jinxuan Pan and Ke Ding*.Identification of GZD824 as an orally bioavailable Bcr-Abl inhibitor overcoming the clinically acquired gene mutation induced resistance against imatinib. Journal of Medicinal Chemistry. 2013, 56, 879-894(IF=5.889)。

推荐链接
down
wechat
bug